Key facts: Merck Q3 Sales Up, EPS Down; Approvals; $550M Boost

What happened

Merck reported third-quarter 2026 sales of $18.09 billion, up 4.7% from a year earlier, while net income fell 12.4% to $5.07 billion and diluted earnings per share declined 12.1% to $2.04. It received U.S. approvals and expanded uses for several medicines, and said U.S. sales included a $550 million boost from purchase timing that it expects to reverse.

Confirmed

Global impact / market context

Sales growth alongside lower net income and earnings per share shows that higher revenue did not translate into higher reported profit this quarter. The expected reversal of the $550 million timing boost could also reduce future sales comparisons, while new approvals and expanded uses may support medicine sales if launched and adopted.

Analyst inference

The article reports both near-term sales support from public-sector Gardasil purchases and purchase timing, and portfolio additions from acquisitions and a licensing deal. These factors point in different directions: temporary purchasing effects may fade, while newly approved medicines and acquired assets may take time to contribute.

Analyst inference

What to watch

1. Watch whether Merck's U.S. sales fall as the company expects the $550 million purchase-timing boost to reverse, and whether public-sector Gardasil purchases remain favorable. Analyst inference
2. Track the planned Lipfendra launch and uptake of newly approved or expanded medicine uses; these will show whether regulatory decisions translate into additional sales. Analyst inference
3. Assess future earnings reports for changes in sales, net income, and diluted earnings per share, which measures profit allocated to each share, after this quarter's divergence. Analyst inference

Evidence

• Original source link unavailable